| Followers | 149 |
| Posts | 2303 |
| Boards Moderated | 0 |
| Alias Born | 01/24/2012 |
Saturday, March 28, 2020 7:36:56 AM
Abbott wins U.S. approval for test that can detect coronavirus in minutes
March 27 (Reuters) - Abbott Laboratories said on Friday it won U.S. marketing approval for a diagnostic test for the coronavirus that can deliver results to patients within minutes[color=red][/color] and be used in physicians offices and urgent care clinics, as well as hospitals.
Abbott Laboratories American Express reports earnings Wednesday, April 18, 2018. (AP Photo/Nam Y. Huh, File)
The United States now has more cases of the coronavirus than any other country, and hospitals have struggled to meet the demand to test thousands of people for the often-deadly virus.
The U.S. Food and Drug Administration granted the approval under its Emergency Use Authorization.
Abbott said in a statement that it plans to begin distributing the test next week and will ramp up manufacturing to 50,000 tests per day.
"This is a significant leap forward," John Frels, vice president of research and development at Abbott, said in an interview with Reuters. "You can get a positive result in five minutes and a negative result in 13 minutes. You can walk into a clinic and literally get results while you are there."
The portable test will run on Abbott's ID NOW platform.
It is the second test to be approved by the FDA that can be used directly in physicians' offices and other community healthcare settings and promptly provide results to patients. Last week, the FDA approved a test made by Cepheid that can be used at the point of care.
"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert Ford, president and chief operating officer at Abbott, in a statement.
Abbott received approval last week for a high volume, automated diagnostic test that can be used in laboratories and said at the time it would immediately distribute 150,000 of the tests around the country.
Between the two platforms, Abbott said it plans to produce 5 million tests per month.
The FDA has been rushing to approve tests for the coronavirus on an emergency basis and has approved others made by companies including Roche Holding AG and Thermo Fisher Scientific Inc.
With the expansion of testing has come a surge in confirmed cases of COVID-19. Reuters reported on Friday that the United States now has more than 100,000 cases. (Reporting by Carl O'Donnell Editing by Leslie Adler)
March 27 (Reuters) - Abbott Laboratories said on Friday it won U.S. marketing approval for a diagnostic test for the coronavirus that can deliver results to patients within minutes[color=red][/color] and be used in physicians offices and urgent care clinics, as well as hospitals.
Abbott Laboratories American Express reports earnings Wednesday, April 18, 2018. (AP Photo/Nam Y. Huh, File)
The United States now has more cases of the coronavirus than any other country, and hospitals have struggled to meet the demand to test thousands of people for the often-deadly virus.
The U.S. Food and Drug Administration granted the approval under its Emergency Use Authorization.
Abbott said in a statement that it plans to begin distributing the test next week and will ramp up manufacturing to 50,000 tests per day.
"This is a significant leap forward," John Frels, vice president of research and development at Abbott, said in an interview with Reuters. "You can get a positive result in five minutes and a negative result in 13 minutes. You can walk into a clinic and literally get results while you are there."
The portable test will run on Abbott's ID NOW platform.
It is the second test to be approved by the FDA that can be used directly in physicians' offices and other community healthcare settings and promptly provide results to patients. Last week, the FDA approved a test made by Cepheid that can be used at the point of care.
"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert Ford, president and chief operating officer at Abbott, in a statement.
Abbott received approval last week for a high volume, automated diagnostic test that can be used in laboratories and said at the time it would immediately distribute 150,000 of the tests around the country.
Between the two platforms, Abbott said it plans to produce 5 million tests per month.
The FDA has been rushing to approve tests for the coronavirus on an emergency basis and has approved others made by companies including Roche Holding AG and Thermo Fisher Scientific Inc.
With the expansion of testing has come a surge in confirmed cases of COVID-19. Reuters reported on Friday that the United States now has more than 100,000 cases. (Reporting by Carl O'Donnell Editing by Leslie Adler)
Recent ABT News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 08:04:06 PM
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test • PR Newswire (US) • 04/17/2026 07:30:00 PM
- Abbott Shares Slip on Weaker Q2 Outlook Despite In-Line Q1 Results • IH Market News • 04/16/2026 02:13:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 11:36:25 AM
- Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences • PR Newswire (US) • 04/16/2026 11:30:00 AM
- New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health • PR Newswire (US) • 04/09/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:31:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:24:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:15:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:07:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:00:50 PM
- Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform • PR Newswire (US) • 03/30/2026 01:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 07:05:51 PM
- Abbott hosts conference call for first-quarter earnings • PR Newswire (US) • 03/26/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 10:56:57 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 10:46:39 PM
- John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening • PR Newswire (US) • 03/24/2026 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/23/2026 09:30:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:54:17 PM
- Abbott completes acquisition of Exact Sciences • PR Newswire (US) • 03/23/2026 12:50:00 PM
- Abbott acquisition of Exact Sciences set to close on March 23, 2026 • PR Newswire (US) • 03/20/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/13/2026 08:01:21 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/13/2026 08:00:23 PM
- Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management • PR Newswire (US) • 03/12/2026 12:00:00 PM
